Insmed Delivers Strategic Business and Clinical Update

Insmed Incorporated has announced significant recent developments concerning its business and clinical efforts. The company has reported on the outcomes of its Phase 2b BiRCh study involving brensocatib, as well as the acquisition of a promising monoclonal antibody.

Outcome of the Phase 2b BiRCh Study

The Phase 2b BiRCh study, which focused on the efficacy of brensocatib in treating chronic rhinosinusitis without nasal polyps (CRSsNP), yielded disappointing results. Neither the primary nor secondary efficacy endpoints were achieved in the trial, which evaluated patients using two dosage levels: 10 mg and 40 mg.

Dr. Martina Flammer, Chief Medical Officer of Insmed, expressed disappointment in the results but acknowledged the clarity they provided. She highlighted that the study aimed to assess whether brensocatib could benefit patients with CRSsNP in the absence of suitable animal models for testing.

Study Results Overview

• Primary Endpoint: Change from baseline to the 28-day average of daily Sinus Total Symptom Score (sTSS) at Week 24 resulted in:
  • Placebo: -2.44
  • Brensocatib 10 mg: -2.21
  • Brensocatib 40 mg: -2.33
• Treatment-Emergent Adverse Events (TEAEs):
  

  Group	Any TEAE (%)	Serious TEAE (%)	Severe TEAE (%)
  Brensocatib 10 mg (N=99)	63.6	2.0	0
  Brensocatib 40 mg (N=93)	69.9	3.2	0
  Placebo (N=95)	65.3	2.1	3.2

As a direct result of these outcomes, Insmed has decided to discontinue the development of brensocatib for CRSsNP and will present the study’s data at a future medical congress.

Acquisition of INS1148

In a strategic move, Insmed has acquired INS1148, an investigational monoclonal antibody with the potential to target respiratory and immunological conditions. This acquisition represents a significant opportunity for Insmed to expand its portfolio, focusing on diseases with high unmet needs.

INS1148 is designed to preferentially target a specific isoform of Stem Cell Factor (SCF248), which plays a crucial role in inflammatory pathways while preserving essential healing processes. Insmed plans to advance its development for conditions including interstitial lung disease and moderate-to-severe asthma.

Dr. Flammer emphasized that this innovative therapy could become a first-in-class treatment, further enriching Insmed’s pipeline of clinical solutions.

About Insmed

Insmed Incorporated is a biopharmaceutical company based in Bridgewater, New Jersey. It is dedicated to delivering groundbreaking therapies for patients with serious diseases. The company maintains a diverse portfolio of approved medicines and investigational therapies, primarily concentrating on pulmonary and inflammatory conditions. Insmed is renowned for its commitment to innovation and patient care, being recognized as a leading employer in the biopharmaceutical industry.